{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T14:14:23Z","timestamp":1758809663946,"version":"3.44.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009898","name":"Defense Health Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ucl.2022.01.001","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T20:53:52Z","timestamp":1649796832000},"page":"309-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hormone Treatment of Prostate Cancer:"],"prefix":"10.1016","volume":"49","author":[{"given":"Muhieddine","family":"Labban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Alkassis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Alkhatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander P.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Kibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib1","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer J Clinicians"},{"issue":"7","key":"10.1016\/j.ucl.2022.01.001_bib2","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jama.1946.02870240008003","article-title":"Prostatic cancer treated by orchiectomy: the five year results","volume":"131","author":"Huggins","year":"1946","journal-title":"J\u00a0Am Med Assoc"},{"author":"Huggins","key":"10.1016\/j.ucl.2022.01.001_bib3"},{"issue":"9327","key":"10.1016\/j.ucl.2022.01.001_bib4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"issue":"3 Suppl 1","key":"10.1016\/j.ucl.2022.01.001_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01560-1","article-title":"Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer","volume":"60","author":"Meng","year":"2002","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"Crawford","year":"2019","journal-title":"Prostate Cancer prostatic Dis"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1245\/s10434-018-7035-z","article-title":"Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status","volume":"26","author":"McClintock","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib8","first-page":"1061","article-title":"Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation","volume":"198","author":"Feldman","year":"2017","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2022.01.001_bib9","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1464-410X.2013.11796.x","article-title":"Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?","volume":"111","author":"Tolkach","year":"2013","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib10","first-page":"14","article-title":"Advanced Prostate Cancer: AUA\/ASTRO\/SUO Guideline PART I","volume":"205","author":"Lowrance","year":"2021","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib11","first-page":"22","article-title":"Advanced Prostate Cancer: AUA\/ASTRO\/SUO Guideline PART II","volume":"205","author":"Lowrance","year":"2021","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.eururo.2004.05.006","article-title":"Hormone Therapy in Prostate Cancer: LHRH Antagonists versus LHRH Analogues","volume":"46","author":"Weckermann","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2022.01.001_bib14","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.13.3.429","article-title":"Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice","author":"Lamharzi","year":"1998","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0090-4295(03)00656-3","article-title":"An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists","volume":"62","author":"Koch","year":"2003","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib16","first-page":"1986","article-title":"A\u00a01-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America","volume":"180","author":"Gittelman","year":"2008","journal-title":"J\u00a0Urol"},{"issue":"11","key":"10.1016\/j.ucl.2022.01.001_bib17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib18","first-page":"889","article-title":"A\u00a0Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer","volume":"186","author":"Crawford","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"23","key":"10.1016\/j.ucl.2022.01.001_bib19","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ucl.2022.01.001_bib20","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","article-title":"Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis","volume":"132","author":"Seidenfeld","year":"2000","journal-title":"Ann Intern Med"},{"issue":"Suppl 7","key":"10.1016\/j.ucl.2022.01.001_bib21","first-page":"S12","article-title":"Challenges with luteinizing hormone-releasing hormone agonists: flare and surge","volume":"6","author":"Brawer","year":"2004","journal-title":"Rev Urol"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib22","first-page":"934","article-title":"Influence of Different Types of Antiandrogens on Luteinizing Hormone-Releasing Hormone Analogue-Induced Testosterone Surge in Patients with Metastatic Carcinoma of the Prostate","volume":"144","author":"Schulze","year":"1990","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000056592","article-title":"Optimal Starting Time for Flutamide to Prevent Disease Flare in Prostate Cancer Patients Treated with a Gonadotropin-Releasing Hormone Agonist","volume":"66","author":"Tsushima","year":"2001","journal-title":"Urologia Int"},{"issue":"801","key":"10.1016\/j.ucl.2022.01.001_bib24","article-title":"Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Review","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib25","first-page":"1264","article-title":"Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018","volume":"200","author":"Lowrance","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib26","first-page":"344","article-title":"The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer","volume":"200","author":"Ryan","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamaoncol.2018.5191","article-title":"Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer\u2014The Forgotten Dance Partner?","volume":"5","author":"Klaassen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2022.01.001_bib28","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ucl.2022.01.001_bib29","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy","volume":"368","author":"Ryan","year":"2012","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib32","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1210\/jcem-59-5-963","article-title":"Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men","volume":"59","author":"Knuth","year":"1984","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib33","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200023050-00003","article-title":"Antiandrogen Withdrawal Syndrome Associated with Prostate Cancer Therapies","volume":"23","author":"Paul","year":"2000","journal-title":"Drug Saf"},{"issue":"8","key":"10.1016\/j.ucl.2022.01.001_bib34","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T","article-title":"The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer","volume":"76","author":"Small","year":"1995","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ucl.2022.01.001_bib35","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.1996.14.8.2250","article-title":"Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol","volume":"14","author":"Chang","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ucl.2022.01.001_bib36","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1464-410X.2010.09319.x","article-title":"Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years","volume":"105","author":"Iversen","year":"2010","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003088-199834050-00005","article-title":"Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer","volume":"34","author":"Mahler","year":"1998","journal-title":"Clin Pharm"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bju.13123","article-title":"Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer","volume":"117","author":"Schalken","year":"2016","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bju.12826","article-title":"Is there an antiandrogen withdrawal syndrome with enzalutamide?","volume":"115","author":"Rodriguez-Vida","year":"2015","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib40","first-page":"119","article-title":"Enzalutamide: The emperor of all anti-androgens","volume":"2","author":"Antonarakis","year":"2013","journal-title":"Transl Androl Urol"},{"issue":"5928","key":"10.1016\/j.ucl.2022.01.001_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"issue":"32","key":"10.1016\/j.ucl.2022.01.001_bib42","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib43","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"Davis","year":"2019","journal-title":"New Engl J Med"},{"issue":"13","key":"10.1016\/j.ucl.2022.01.001_bib44","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib46","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1470-2045(18)30898-2","article-title":"Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial","volume":"20","author":"Tombal","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2022.01.001_bib47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14737140.2018.1503954","article-title":"Apalutamide for the treatment of prostate cancer","volume":"18","author":"Rathkopf","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"15","key":"10.1016\/j.ucl.2022.01.001_bib48","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer","volume":"378","author":"Smith","year":"2018","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","volume":"381","author":"Chi","year":"2019","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib50","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Scientific Rep"},{"issue":"9","key":"10.1016\/j.ucl.2022.01.001_bib51","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1586\/14737140.2015.1081566","article-title":"ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer","volume":"15","author":"Fizazi","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"issue":"13","key":"10.1016\/j.ucl.2022.01.001_bib52","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"New Engl J Med"},{"issue":"26","key":"10.1016\/j.ucl.2022.01.001_bib53","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1016\/j.ucl.2022.01.001_bib54","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41585-020-0335-7","article-title":"Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer","volume":"17","author":"Perera","year":"2020","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib55","first-page":"2361","article-title":"Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy","volume":"167","author":"Berruti","year":"2002","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib57","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","article-title":"Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer","volume":"2","author":"Hershman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.ucl.2022.01.001_bib58","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN Task Force Report: Bone Health In Cancer Care","volume":"11","author":"Gralow","year":"2013","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"11","key":"10.1016\/j.ucl.2022.01.001_bib59","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1007\/s11606-013-2477-2","article-title":"Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer","volume":"28","author":"Shahinian","year":"2013","journal-title":"J\u00a0Gen Intern Med"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.6004\/jnccn.2021.0008","article-title":"NCCN Guidelines Insights: Prostate Cancer, Version 1.2021","volume":"19","author":"Schaeffer","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","article-title":"Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"15","author":"Serpa Neto","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib62","doi-asserted-by":"crossref","first-page":"e0117344","DOI":"10.1371\/journal.pone.0117344","article-title":"Quantifying the Evidence for the Risk of Metabolic Syndrome and Its Components following Androgen Deprivation Therapy for Prostate Cancer: A Meta-Analysis","volume":"10","author":"Bosco","year":"2015","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib63","first-page":"573","article-title":"Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer","volume":"200","author":"Gild","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib64","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.critrevonc.2008.06.006","article-title":"Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study","volume":"68","author":"van Londen","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"10.1016\/j.ucl.2022.01.001_bib65","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/0026-0495(90)90297-P","article-title":"Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels","volume":"39","author":"Seidell","year":"1990","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib66","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.urology.2014.02.006","article-title":"Weight gain on androgen deprivation therapy: which patients are at highest risk?","volume":"83","author":"Seible","year":"2014","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib67","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer","volume":"91","author":"Smith","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"27","key":"10.1016\/j.ucl.2022.01.001_bib68","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"Dockery","year":"2003","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000342814","article-title":"Analysis of the lipid profile and atherogenic risk during androgen deprivation therapy in prostate cancer patients","volume":"90","author":"Salvador","year":"2013","journal-title":"Urol Int"},{"issue":"9","key":"10.1016\/j.ucl.2022.01.001_bib71","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib72","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer","volume":"87","author":"Smith","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9\u201310","key":"10.1016\/j.ucl.2022.01.001_bib73","doi-asserted-by":"crossref","first-page":"E300","DOI":"10.5489\/cuaj.3655","article-title":"Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy","volume":"10","author":"Rezaei","year":"2016","journal-title":"Can Urol Assoc J"},{"issue":"11","key":"10.1016\/j.ucl.2022.01.001_bib74","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O'Farrell","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib75","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2826.2011.02119.x","article-title":"The heart: a novel\u00a0gonadotrophin-releasing hormone target","volume":"23","author":"Dong","year":"2011","journal-title":"J\u00a0Neuroendocrinol"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib76","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","article-title":"Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism","volume":"61","author":"Hu","year":"2012","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib77","first-page":"1226","article-title":"Influence of age on incident diabetes and cardiovascular disease in prostate cancer survivors receiving androgen deprivation therapy","volume":"193","author":"Morgans","year":"2015","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib78","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib79","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bju.13203","article-title":"Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events","volume":"118","author":"Schmid","year":"2016","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/bju.15059","article-title":"Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists","volume":"126","author":"Cone","year":"2020","journal-title":"BJU Int"},{"issue":"21","key":"10.1016\/j.ucl.2022.01.001_bib81","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib82","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2016.35","article-title":"A\u00a0meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients","volume":"19","author":"Jin","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"30","key":"10.1016\/j.ucl.2022.01.001_bib83","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1200\/JCO.2012.41.8509","article-title":"Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer","volume":"30","author":"Higano","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib84","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41443-021-00418-7","article-title":"Sexual function in men undergoing androgen deprivation therapy","volume":"33","author":"Corona","year":"2021","journal-title":"Int J Impot Res"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib85","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.urology.2012.08.068","article-title":"Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone","volume":"81","author":"Parekh","year":"2013","journal-title":"Urology"},{"issue":"14","key":"10.1016\/j.ucl.2022.01.001_bib86","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib87","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cncr.10656","article-title":"The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma","volume":"95","author":"Fowler","year":"2002","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib88","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1530\/ERC-15-0456","article-title":"Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials","volume":"23","author":"Teleni","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib89","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jamaoncol.2016.3662","article-title":"Association Between Androgen Deprivation Therapy and Risk of Dementia","volume":"3","author":"Nead","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2022.01.001_bib90","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/iju.13409","article-title":"Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer","volume":"24","author":"Dinh","year":"2017","journal-title":"Int J Urol"},{"issue":"16","key":"10.1016\/j.ucl.2022.01.001_bib91","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2015.64.1969","article-title":"Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer","volume":"34","author":"Dinh","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1532-5415.2005.00567.x","article-title":"Quality of life in prostate cancer patients taking androgen deprivation therapy","volume":"54","author":"Dacal","year":"2006","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib93","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41391-019-0189-3","article-title":"Risk of dementia following androgen deprivation therapy for treatment of prostate cancer","volume":"23","author":"Krasnova","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib94","first-page":"1417","article-title":"Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis","volume":"199","author":"Sun","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.euo.2019.08.003","article-title":"Risk of Dementia and Depression in Young and Middle-aged Men Presenting with Nonmetastatic Prostate Cancer Treated with Androgen Deprivation Therapy","volume":"4","author":"Tully","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.ucl.2022.01.001_bib96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bju.12964","article-title":"Adverse effects of androgen-deprivation therapy in prostate cancer and their management","volume":"115","author":"Rhee","year":"2015","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib97","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2022.01.001_bib98","doi-asserted-by":"crossref","DOI":"10.2196\/20224","article-title":"Mobile Health App for Prostate Cancer Patients on Androgen Deprivation Therapy: Qualitative Usability Study","volume":"8","author":"Nabi","year":"2020","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.ucl.2022.01.001_bib99","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2016.10.007","article-title":"Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials","volume":"108","author":"Menichetti","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.ucl.2022.01.001_bib100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat Clin Pract Urol"},{"issue":"32","key":"10.1016\/j.ucl.2022.01.001_bib101","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib102","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6601127","article-title":"Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer","volume":"89","author":"Edwards","year":"2003","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ucl.2022.01.001_bib103","first-page":"1541","article-title":"Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone","volume":"7","author":"Culig","year":"1993","journal-title":"Mol Endocrinol"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib104","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/76287","article-title":"Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor","volume":"6","author":"Zhao","year":"2000","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ucl.2022.01.001_bib105","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib106","first-page":"806","article-title":"Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Na\u00efve Patients with Advanced Prostate Cancer?","volume":"205","author":"Patel","year":"2021","journal-title":"J\u00a0Urol"},{"issue":"12","key":"10.1016\/j.ucl.2022.01.001_bib107","article-title":"The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Na\u00efve Prostate Cancer Patients","volume":"7","author":"Sasaki","year":"2018","journal-title":"J\u00a0Clin Med"},{"issue":"24","key":"10.1016\/j.ucl.2022.01.001_bib108","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1200\/JCO.2006.06.4246","article-title":"Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)","volume":"24","author":"Hussain","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib109","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.euo.2020.07.001","article-title":"Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial","volume":"3","author":"Bryce","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2022.01.001_bib110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpdd.132","article-title":"Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin","volume":"4","author":"Bernard","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ucl.2022.01.001_bib111","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"10.1016\/j.ucl.2022.01.001_bib112","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s40262-016-0403-6","article-title":"Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide","volume":"55","author":"Benoist","year":"2016","journal-title":"Clin Pharm"},{"issue":"7","key":"10.1016\/j.ucl.2022.01.001_bib113","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/jcph.253","article-title":"Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment","volume":"54","author":"Marbury","year":"2014","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib114","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.eururo.2013.12.063","article-title":"Disease Control Outcomes from Analysis of Pooled Individual Patient Data from Five Comparative Randomised Clinical Trials of Degarelix Versus Luteinising Hormone-releasing Hormone Agonists","volume":"66","author":"Klotz","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2022.01.001_bib115","first-page":"1199","article-title":"Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease","volume":"202","author":"Margel","year":"2019","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2022.01.001_bib116","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-137-7-200210010-00029","article-title":"Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect","volume":"137","author":"Bennett","year":"2002","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ucl.2022.01.001_bib117","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/14656566.1.3.443","article-title":"Non-steroidal anti-androgens in prostate cancer--current treatment practice","volume":"1","author":"Han","year":"2000","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.ucl.2022.01.001_bib118","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000081585","article-title":"Hepatotoxicity Induced by Antiandrogens: A Review of the Literature","volume":"73","author":"Thole","year":"2004","journal-title":"Urologia Int"},{"issue":"2 Suppl","key":"10.1016\/j.ucl.2022.01.001_bib119","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0090-4295(91)80096-P","article-title":"Pharmacokinetics and metabolism of nilutamide","volume":"37","author":"Creaven","year":"1991","journal-title":"Urology"},{"issue":"10","key":"10.1016\/j.ucl.2022.01.001_bib120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-018-0077-y","article-title":"The role of ketoconazole in current prostate cancer care","volume":"15","author":"Patel","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.ucl.2022.01.001_bib121","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jgo.2020.11.002","article-title":"Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review","volume":"12","author":"Batra","year":"2021","journal-title":"J\u00a0Geriatr Oncol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014322000015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014322000015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:56:46Z","timestamp":1758808606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014322000015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":121,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0094014322000015"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2022.01.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hormone Treatment of Prostate Cancer:","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2022.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}